Research programme : Anti-S100A9 monoclonal antibodies - InflammatoRx
Latest Information Update: 20 Sep 2023
Price :
$50 *
At a glance
- Originator InflammatoRx
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action S100 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammation; Neurodegenerative disorders
Most Recent Events
- 20 Sep 2023 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
- 20 Sep 2023 Discontinued - Preclinical for Neurodegenerative disorders in Canada (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Inflammation in Canada